New PET tracer aims to spot scarring in organs without a needle

NCT ID NCT07459205

Not yet recruiting Diagnosis Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test a new imaging agent called 68Ga-1A12, which is used in a PET scan to detect fibrosis (scarring) in organs like the lungs. The goal is to see if this scan can diagnose fibrosis earlier and more accurately than current methods, which often require invasive biopsies. The study plans to enroll 50 adults with suspected or confirmed fibrosis-related disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-1A12 (a radioactive tracer for PET imaging)
What this could lead to: If successful, this could provide a non-invasive way to detect and monitor fibrosis earlier and more accurately than current methods.
What could go wrong: This is a small, early-stage study (50 participants) focused on diagnostic accuracy, not treatment. The tracer may not prove reliable enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBROUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIBROUS PULMONARY FIBROSIS

Contacts and locations

Locations

Daping Hospital

Chongqing, Chongqing Municipality, 400010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.